Navigation Links
Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
Date:2/23/2011

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array (SiMoA™) technology by combining digital and analog detection in one straightforward measurement.  The article appears in the journal Analytical Chemistry, and highlights the ability to precisely measure proteins present at not only extremely low levels, but higher concentrations as well, effectively extending the dynamic range of immunoassays from the picomolar level down to sub-femtomolar levels in a single measurement.  

"Many diagnostic applications require tests to be sensitive as well as perform over a broad spectrum of concentrations to allow target analytes to be measured in the majority of clinical samples.  By combining the Quanterix digital approach for single molecule detection with ensemble measurements, we are able to measure proteins over a wider range than either method alone," said David Duffy, Ph.D., corresponding author of the article.

David Okrongly, Ph.D., President and CEO of Quanterix added, "The ability to accurately measure proteins over a larger concentration range, down to sub-femtomolar levels, further moves the company towards our stated goal of providing a universal platform that will improve the quality and clinical value of immunodiagnostics.  This expansion of our SiMoA technology allows us to deliver the most sensitive and precise results without sacrificing assay throughput or increasing cost in the clinical setting."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Announces New Technology Evaluation Agreement
2. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
3. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
4. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
5. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
6. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
7. Sensus Healthcare Announces the Formation of a Medical Advisory Board
8. Sigma-Aldrich Announces Organizational Changes
9. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
10. MiMedx Announces Launch of AmnioFix™
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... ALBANY, New York , November 30, 2016 /PRNewswire/ ... exceptionally consolidated as a few players hold a dominant ... Lonza Group, Charles River Laboratories International, Inc., and Merck ... global market in 2015. Transparency Market Research observes that ... they are focused on development products that are do ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
Breaking Biology News(10 mins):